eccogene glp-1

eccogene glp-1 Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist - Haggag - 2025 - Diabetes, Obesity and Metabolism Eccogene raises funds for metabolic

Name: eccogene glp-1 Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist - Haggag - 2025 - Diabetes, Obesity and Metabolism Eccogene raises funds for metabolic
Brand: actil.am
SKU: 53686482356
Price: 20.62 USD
Availability: InStock
Rating: 4.4698 (16 reviews)

SKU: 53686482356

4.5

USD20.62 USD43.62

Pay in 4 interest-free payments of $5.16 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 27 - Sep 1

Description

Pharmacologic evaluation of sulfasalazine, FTY720, and anti-IL-12/23p40 in a TNBS-induced Crohns disease model

They are not experimental molecules with uncertain clinical relevance

Medications, such as semaglutide and tirzepatide, have become popular over the past few years to help people lose weight

Heart health (Major Adverse Cardiovascular Events MACE) early evidence suggests a possible cardiovascular benefit, with a large dedicated outcomes trial underway to confirm this (JAMA Network Open, 2024)